Compare ARAI & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARAI | CTXR |
|---|---|---|
| Founded | 2020 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.4M | 18.7M |
| IPO Year | 2024 | 2010 |
| Metric | ARAI | CTXR |
|---|---|---|
| Price | $0.23 | $0.60 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $12.00 | $6.00 |
| AVG Volume (30 Days) | 565.5K | ★ 982.8K |
| Earning Date | 04-15-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.38 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $113,250.00 | N/A |
| Revenue This Year | $800.66 | N/A |
| Revenue Next Year | $650.00 | $147.57 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.22 | $0.47 |
| 52 Week High | $6.86 | $2.19 |
| Indicator | ARAI | CTXR |
|---|---|---|
| Relative Strength Index (RSI) | 33.77 | 50.44 |
| Support Level | $0.22 | $0.51 |
| Resistance Level | $0.30 | $0.76 |
| Average True Range (ATR) | 0.02 | 0.06 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 13.61 | 29.57 |
Arrive AI Inc is a technology company. Its patented Autonomous Last Mile (ALM) platform enables secure, efficient delivery to and from a smart, AI-powered mailbox-whether by drone, ground robot, or human courier. The platform provides real-time tracking, smart logistics alerts, and advance chain-of-custody controls to support shippers, delivery services, and autonomous networks. By combining artificial intelligence with autonomous technology, Arrive AI makes the exchange of goods between people, robots, and drones frictionless and convenient. Its system integrates with smart home devices such as doorbells, lighting, and security systems to streamline the entire last-mile delivery experience.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.